A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas
Latest Information Update: 24 Aug 2020
At a glance
- Drugs Fimaporfin/gemcitabine (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Cholangiocarcinoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors PCI Biotech
- 19 Aug 2020 According to a PCI Biotech media release, a case report series from the study is accepted for publishing in Endoscopy International Open and ill soon be available online.
- 28 Oct 2019 Status changed from recruiting to completed.
- 10 Jul 2019 According to European Clinical Trials Database record, trial is Prematurely Ended at Germany, Lithuania and completed at France, Austria Norway and ongoing at UK.